2168-75-4

Usage

InChI:InChI=1/C13H13I3N2O4/c1-4-22-13(21)7-8(14)11(17-5(2)19)10(16)12(9(7)15)18-6(3)20/h4H2,1-3H3,(H,17,19)(H,18,20)

Upstream product

• 117-96-4 diatrizoic acid 
• 75-03-6 ethyl iodide 

Downstream Products

• 34951-99-0 3,5-Bis-[acetyl-(4-bromo-butyl)-amino]-2,4,6-triiodo-benzoic acid ethyl ester 

Relevant academic research and scientific papers

Embolus therapy using insoluble microparticles or vesicles containing contrast agents

The invention provides a method of embolus therapy comprising administering into the vasculature of a perfused zone of tissue in a human or non-human animal subject a composition comprising particles of a size or formulation selected to generate emboli at

Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents

Nanoparticulate crystalline x-ray contrast agents are formulated with stabilizers to enhance contact between the crystalline x-ray contrast agents and the gastrointestinal tract. Nanoparticulate crystalline therapeutic substances also formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the gastrointestinal tract and to provide extended therapeutic effect.

Polyalkylene block copolymers as surface modifiers for nanoparticles

There is disclosed a composition containing nanoparticles having a surface modifier wherein the surface modifier is a block copolymer containing one or more polyoxyethylene blocks and one or more polyoxy(higher alkylene) blocks wherein at least some of the blocks are linked together by a linking group characterized in that the linking group is an oxymethylene group.

Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays

Nanoparticulate crystalline substances formulated with stabilizers and pharmaceutically acceptable clays to enhance contact between the crystalline substances and the gastrointestinal tract. These formulations have improved safety profiles, a low potential for absorption, are not viscous and are not contraindicated for GI perforations or intestinal obstructions. The properties of the surfactant stabilizers are independent of the crystalline drug used and largely determine the extent to which the formulation coats the GI tract.

X-ray contrast compositions useful in medical imaging

An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, and a pharmaceutically acceptable carrier therefor is useful in x-ray diagnostic medical imaging methods. The agents can be delivered to a specific tissue or fluid site, for example, the blood pool, liver or spleen. In one embodiment involving intravenous administration, preferred compositions provide effective imaging of the blood pool for remarkably long times.

X-ray contrast compositions containing an organic crystalline X-ray contrast agent in combination with pharmaceutically acceptable clays

Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a crystalline organic constrast agent in combination with a pharmaceutically acceptable clay in a pharmaceutically acceptable carrier; and methods for their use in diagnostic radiology of the gastrointestinal tract.

Polymeric x-ray contrast compositions containing an organic crystalline x-ray contrast agent

Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a polymeric material in combination with a divalent cation capable of forming a coating on the gastrointestinal tract and a crystalline contrast agent in a pharmaceutically acceptable carrier; and methods for their use in diagnostic radiology of the gastrointestinal tract.